Drugs / revexepride
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01786876 | Mar → Apr 2013 | — | Shire | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01370863 | Dec 2010 → May 2012 | gastroesophageal reflux disease | Shire | Terminated | Missed primary Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01472939 Comparator | Feb 2012 → May 2013 | gastroesophageal reflux disease | Shire | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | revexepride | “The aim of this study was to assess the pharmacodynamic effect of the prokinetic agent revexepride (a 5-HT4 receptor agonist) in patients with GERD who have persistent symptoms...” PMID 25530111 ↗ Dec 20141“Randomised clinical trial: the 5-HT4 agonist revexepride in patients with” PMID 25693609 ↗ Feb 2015 |
| Known as | SPD557 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01786876 ↗ |
| Action | Activate | “the prokinetic agent revexepride (a 5-HT4 receptor agonist)” PMID 25530111 ↗ Dec 2014 |